Climb Bio (CLYM) Current Leases (2022 - 2026)
Climb Bio's (CLYM) quarterly Current Leases came in at $263000.0 in Q1 2026, up 69.68% YoY from $155000.0 in Q1 2025, and up 2.73% on a QoQ basis from $256000.0 in Q4 2025.
Climb Bio (CLYM) Current Leases (2022 - 2026) Analysis & Trends
Climb Bio (CLYM) has 5 years of Current Leases data on file, last reported at $263000.0 in Q1 2026.
- Quarterly Current Leases rose 69.68% year-over-year to $263000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263000.0 (up 69.68% YoY) and the FY2025 annual result came in at $256000.0, up 63.06% from the prior year.
- Current Leases grew to $263000.0 in Q1 2026, from $256000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $485000.0 in Q2 2023 to a low of $58000.0 in Q3 2024.
- A 5-year average of $288117.6 and a median of $263000.0 in 2026 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases sank 85.54% — and 2025, when it soared 293.1%.
- Tracing CLYM's Current Leases over 5 years: stood at $300000.0 in 2022, then advanced by 11.33% to $334000.0 in 2023, then plunged by 52.99% to $157000.0 in 2024, then jumped by 63.06% to $256000.0 in 2025, then rose by 2.73% to $263000.0 in 2026.
- The last three Current Leases figures came in at $263000.0 (Q1 2026), $256000.0 (Q4 2025), and $228000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 501,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 501,000.00 |
| Mar 31, 2026 | 263,000.00 |
| Dec 31, 2025 | 256,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 222,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 225,000.00 |
| Dec 31, 2023 | 334,000.00 |
| Sep 30, 2023 | 401,000.00 |
| Jun 30, 2023 | 485,000.00 |
| Mar 31, 2023 | 464,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | 352,000.00 |
| Jun 30, 2022 | 439,000.00 |
| Mar 31, 2022 | 459,000.00 |